Show simple item record

dc.contributor.authorMochol, Monika
dc.contributor.authorTaubøll, Erik
dc.contributor.authorAukrust, Pål
dc.contributor.authorUeland, Thor
dc.contributor.authorAndreassen, Ole
dc.contributor.authorSvalheim, Sigrid
dc.date.accessioned2024-01-30T08:02:12Z
dc.date.available2024-01-30T08:02:12Z
dc.date.issued2023-02-07
dc.description.abstractObjectives. Blood-brain barrier (BBB) dysfunction is one of the key pathogenic mechanisms in the development of epilepsy. There is therefore an increasing need to identify BBB biomarkers as these will have prognostic and therapeutic implications. The purpose of this study was to assess the levels of the BBB permeability markers, glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE), S100B, and furin in patients with stable epilepsy compared with the levels in healthy controls. Materials and Methods. This cross-sectional study included 119 epilepsy patients and 80 healthy controls. Circulating levels of GFAP, NSE, S100B, and furin were measured and questionnaires regarding epilepsy, use of drugs, and comorbidities were completed by all participants. Results. GFAP levels were higher in epilepsy patients after adjustment for potential confounders (sex, age, and BMI) in linear regression (p = 0:042). No significant differences were found in levels of S100B, NSE, or furin. None of the markers were significantly associated with epilepsy duration, seizure type or severity, or seizures in the preceding six months. The majority of the patients (79.7%) did not report seizures within the last 6 months. Conclusion. Our main finding is elevated serum levels of GFAP in epilepsy patients. The results may suggest the presence of astrocyte activation in our patient population with stable epilepsy. Future prospective studies focusing on the longitudinal relationship between epilepsy debut, seizures, and time of blood sampling for BBB markers, also within CSF, could provide valuable knowledge including regarding novel treatment options. The study registration number is 2011/1096, 2018/1437.en_US
dc.identifier.citationMochol, Taubøll, Aukrust, Ueland, Andreassen, Svalheim. Serum Markers of Neuronal Damage and Astrocyte Activity in Patients with Chronic Epilepsy: Elevated Levels of Glial Fibrillary Acidic Protein. Acta Neurologica Scandinavica. 2023;2023:1-5en_US
dc.identifier.cristinIDFRIDAID 2202547
dc.identifier.doi10.1155/2023/7246373
dc.identifier.issn0001-6314
dc.identifier.issn1600-0404
dc.identifier.urihttps://hdl.handle.net/10037/32761
dc.language.isoengen_US
dc.publisherHindawien_US
dc.relation.journalActa Neurologica Scandinavica
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleSerum Markers of Neuronal Damage and Astrocyte Activity in Patients with Chronic Epilepsy: Elevated Levels of Glial Fibrillary Acidic Proteinen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)